Agilus Neuro

Making the Invisible Signs of Alzheimer's Visible

Making the Invisible Signs of Alzheimer’s Visible

Agilus Neuro develops ultrasensitive electrochemical biosensors for point-of-care diagnostics. Our proprietary redox-capacitance platform rapidly detects neurodegenerative biomarkers directly in complex biofluids, enabling scalable, decentralized clinical triaging to overcome current bottlenecks in disease management."

One Platform. Endless Possibilities.

Core Sensing Technology Featured In NY Times, Time Magazine, and MIT Tech Review

what we do

Specific
Detection

At Agilus Neuro, our goal is to secure your environment and health through advanced sensing technologies. We design and manufacture end-to-end solutions to detect biomarkers with unprecedented speed and accuracy in complex media

Multiplex
Detection

Born as a spin-off from Washington University in St. Louis, we are bridging the gap between academic rigor and real-world applications. Whether you need early detection or ongoing monitoring of Alzheimer's disease, Agilus Neuro provides the Sample-to-Answer solution you need — from plasma to answer

Born as a spin-off from Washington University in St. Louis, we are bridging the gap between academic rigor and real-world applications. Whether you need early detection or ongoing monitoring of Alzheimer’s disease, Agilus Neuro provides the Sample-to-Answer solution you need — from plasma to answer

Fast
Detection

We believe that rapid detection is the key to early intervention and better outcomes. That is why we offer a holistic ecosystem: robust hardware for plasma sample collection, advanced anti-fouling label-free electrochemical biosensors for detection, and intuitive UI/UX software for real-time data analysis

latest

TauTRACE

Blood-based sensor that detects and stages Alzheimer's disease biomarkers in under 30 minutes, using dual-channel technology to determine disease progression and treatment eligibility

Explore TauTRACE →

TauTRACE

Blood-based sensor that detects and stages Alzheimer’s disease biomarkers in under 30 minutes, using dual-channel technology to determine disease progression and treatment eligibility

Explore TauTRACE →